GlassScriptPhysician profile
Joel Hyman
NPI 1881774818
$22,402.57
in general payments reported to CMS, 2019-2025
33 companies · $3,597 in 2025
The $3,597 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,634 · 2020: $525 · 2021: $2,949 · 2022: $2,457 · 2023: $2,907 · 2024: $2,334 · 2025: $3,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,455 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,454.70 |
| Education | $382.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $5,862.08 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $3,313.34 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $2,345.72 | 2019-2025 | |
| Janssen Biotech, INC. | $1,999.96 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $1,634.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,397.79 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $899.54 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $713.10 | 2019-2025 | |
| Ucb, INC. | $683.10 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $645.00 | 2019-2025 | |
| Amgen INC. | $621.47 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $389.95 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $288.03 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $271.90 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $206.90 | 2019-2025 | Cabtreo, Jublia, Arazlo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $163.45 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.73 | 2023-2025 | Spevigo, Cyltezo |
| Janssen Scientific Affairs, LLC | $121.87 | 2022 | |
| Hill Dermaceuticals, INC. | $120.39 | 2022-2023 | Tolak |
| Revance Therapeutics, INC. | $108.61 | 2025 | Daxxify |
| Celgene Corporation | $95.76 | 2019 | |
| Allergan, INC. | $71.56 | 2019-2022 | |
| Epi Health, LLC | $61.07 | 2019-2022 | |
| Sanofi US Services INC. | $36.99 | 2024 | |
| Botanix Sb INC | $36.85 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $28.09 | 2023 | Vtama |
| Genentech USA, INC. | $24.74 | 2019 | |
| Almirall LLC | $23.05 | 2019 | |
| Springworks Therapeutics, INC. | $21.37 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $19.52 | 2025 | Ycanth |
| Organon LLC | $18.38 | 2025 | Vtama |
| Dermira, INC. | $16.93 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.